• Filament Health shipped PEX010 to the University of Washington for an investigator-initiated Phase 2a trial in cancer-related anxiety, depression.
• Licence agreement covers supply of Filament’s patented, GMP botanical psilocybin candidate for the group retreat therapy study (NCT07336238).
• Trial targets adults with metastatic solid tumors or incurable hematologic malignancies; UW’s Anthony Back is sponsor and principal investigator.
• Filament is not sponsoring the trial, limiting operational responsibility to drug supply.
• PEX010 supply supports Filament’s broader strategy as a pharmaceutical-grade natural psilocybin supplier to more than 80 research studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.